- Home
- Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- Amyloidosis
- Heart Failure
Available Credit:
- 1.00
Course Published On:
Course Expiry Date:
Overview
This micro-learning series focuses on the forefront of cardiac amyloidosis, a rapidly advancing field in healthcare. Providing a focused and tailored update for key healthcare practitioners seeking to enhance their understanding of the latest developments in the diagnosis and treatment of cardiac amyloidosis and its consequences. Throughout this series, esteemed faculty delve into the intricate nature of amyloidosis, offering insights into the evolving management practices in cardiac amyloidosis. This educational journey navigates the nuances of diagnosing cardiac amyloidosis, emphasising the ability to distinguish between various types of the disease, addressing common pitfalls in assessment and underscoring the importance of a collaborative interdisciplinary approach.
Support Statement
This programme is supported by an unrestricted educational grant from AstraZeneca who had no involvement in the creation of the content.
Disclosure
In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 3 years and upcoming 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
The session, ‘Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity.
EBAC® holds agreements on:
- Mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada.
- CME credit conversion with the American Medical Association (AMA).
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of participation in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Instruction to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Target Audience
- Cardiologists
- Imaging Specialists
- Electrophysiologists
- Primary Care Practitioners
- Haematologists
- Cardiac Nurse Practitioners
Learning Objectives
Upon completion of this activity, participants will be able to:
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Module |
Title |
Duration |
Speakers |
---|---|---|---|
Part 1 | An Overview of Amyloidosis: Cardiac and Non-Cardiac Features | 5m 35s | Philip Hawkins |
Part 2 | Cardiac Magnetic Resonance (CMR) in Amyloidosis | 6m 16s | Marianna Fontana |
Part 3 | Light Chain (AL) Amyloidosis: The Importance of Early Diagnosis | 7m 10s | Paolo Milani |
Part 4 | Hereditary TTR amyloidosis: Diagnosis and Treatment | 7m 17s | Julian Gillmore |
Part 5 | How to Manage a Person With a Mutant TTR Gene and No Symptoms? | 9m 2s | Laura Obici |
Part 6 | Diagnosing Wild-Type TTR Amyloidosis (ATTRwt) | 6m 56s | Pablo Garcia-Pavia |
Part 7 | Cardiac Amyloidosis: Non-pharmacologic Therapy (ICD Use) | 5m 35s | Carol Whelan |
Part 8 | Clinical Trials in Cardiac Amyloidosis: Targeting the Precursor Protein | 4m 15s | Julian Gillmore |
Part 9 | PYP and DPD Imaging for the Diagnosis of Transthyretin Amyloidosis | 6m 13s | Philip Hawkins |
Part 10 | Echocardiography in Amyloidosis | 6m 7s | Carol Whelan |
Part 11 | Cardiac Amyloidosis: Cardiology and the Multidisciplinary Team | 6m 27s | Finn Gustafsson |
Part 12 | Should I Set Up My Own Amyloidosis Program? | 10m 13s | Márcia Waddington-Cruz |
An Overview of Amyloidosis: Cardiac and Non-Cardiac Features
Duration: 5m 35s
Speakers: Philip Hawkins
Light Chain (AL) Amyloidosis: The Importance of Early Diagnosis
Duration: 7m 10s
Speakers: Paolo Milani
How to Manage a Person With a Mutant TTR Gene and No Symptoms?
Duration: 9m 2s
Speakers: Laura Obici
Clinical Trials in Cardiac Amyloidosis: Targeting the Precursor Protein
Duration: 4m 15s
Speakers: Julian Gillmore
PYP and DPD Imaging for the Diagnosis of Transthyretin Amyloidosis
Duration: 6m 13s
Speakers: Philip Hawkins
Cardiac Amyloidosis: Cardiology and the Multidisciplinary Team
Duration: 6m 27s
Speakers: Finn Gustafsson
Speaker